ID27415A - Komposisi farmaseutik - Google Patents

Komposisi farmaseutik

Info

Publication number
ID27415A
ID27415A IDW20002745A ID20002745A ID27415A ID 27415 A ID27415 A ID 27415A ID W20002745 A IDW20002745 A ID W20002745A ID 20002745 A ID20002745 A ID 20002745A ID 27415 A ID27415 A ID 27415A
Authority
ID
Indonesia
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
IDW20002745A
Other languages
English (en)
Indonesian (id)
Inventor
Hiroyuki Odaka
Masahiro Yamane
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of ID27415A publication Critical patent/ID27415A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW20002745A 1998-06-30 1999-06-29 Komposisi farmaseutik ID27415A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18370098 1998-06-30

Publications (1)

Publication Number Publication Date
ID27415A true ID27415A (id) 2001-04-05

Family

ID=16140426

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002745A ID27415A (id) 1998-06-30 1999-06-29 Komposisi farmaseutik

Country Status (16)

Country Link
US (2) US6329403B1 (fr)
EP (1) EP1093370B1 (fr)
KR (1) KR20010043455A (fr)
CN (1) CN1305376A (fr)
AR (1) AR019727A1 (fr)
AT (1) ATE318138T1 (fr)
AU (1) AU754740B2 (fr)
BR (1) BR9911656A (fr)
CA (1) CA2329004C (fr)
DE (1) DE69929996T2 (fr)
DK (1) DK1093370T3 (fr)
ES (1) ES2255316T3 (fr)
ID (1) ID27415A (fr)
NO (1) NO20006630L (fr)
WO (1) WO2000000195A1 (fr)
ZA (1) ZA200006262B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
WO2000078333A2 (fr) 1999-06-21 2000-12-28 Eli Lilly And Company Utilisation combinee de thiazolidinediones et de peptide-1 de type glucagone et d'agonistes de ces derniers pour traiter l'instabilite metabolique associee aux diabetes non insulino-dependants.
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
EP1295609A4 (fr) * 2000-02-24 2004-11-03 Takeda Chemical Industries Ltd Medicaments contenant des ingredients actifs combines
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
JP2004331500A (ja) * 2001-02-16 2004-11-25 Dainippon Pharmaceut Co Ltd 血中濃度制御製剤
US20040143015A1 (en) * 2001-03-12 2004-07-22 Villhauer Edwin Bernard Combination of organic compounds
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
WO2002081751A2 (fr) * 2001-04-03 2002-10-17 The Regents Of The University Of California Procede permettant d'augmenter la production de leptine endogene
US20070203225A1 (en) * 2001-04-03 2007-08-30 Havel Peter J Method of increasing endogenous adiponectin production and leptin production
JP2002360666A (ja) * 2001-06-11 2002-12-17 Takeda Chem Ind Ltd コバルト合金を用いた打錠用杵臼
JP2005518408A (ja) 2001-12-29 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ 異常脂肪血症を治療するための、ｇｌｐ−１化合物と他の薬物との組み合わせ使用
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2003063889A1 (fr) * 2002-01-31 2003-08-07 Joslin Diabetes Center, Inc. Procedes de modulation de la fonction des lymphocytes b
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
EP1388352A1 (fr) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Utilisation d'un agoniste de PPAR-alpha pour traiter l'obesité associée au traitement avec un agonist de PPAR-gamma dans des patients
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004078716A1 (fr) * 2003-03-03 2004-09-16 Merck & Co. Inc. Derives de piperazine acyles utilises comme agonistes des recepteurs de la melanocortine 4
US20050187266A1 (en) * 2003-04-15 2005-08-25 Pfizer Inc Alpha substituted carboxylic acids
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US7008957B2 (en) * 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
EP2140865A1 (fr) * 2003-11-14 2010-01-06 Vertex Pharmaceuticals Incorporated Thiazoles et oxazoles utiles en tant que modulateurs de transporteurs de cassette à liaison ATP
EP1727559A1 (fr) * 2004-01-26 2006-12-06 Eli Lilly And Company Utilisation de fgf-21 et d'une thiazolidinedione pour traiter le diabete de type 2
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
WO2005092040A2 (fr) * 2004-03-22 2005-10-06 The Regents Of The University Of California Formulation pour ameliorer la production de leptine et d'adiponectine endogene
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
GB2435770B (en) * 2004-12-03 2010-05-05 Vetco Gray Scandinavia As Hybrid control system and method
KR100697983B1 (ko) * 2005-07-08 2007-03-23 대봉엘에스 주식회사 신규 중간체 및 이를 이용한 피오글리타존의 제조방법
KR100697982B1 (ko) * 2005-07-08 2007-03-23 대봉엘에스 주식회사 로시글리타존의 제조방법
US20070129444A1 (en) * 2005-12-06 2007-06-07 Mallinckrodt Inc. Novel weight reduction composition and uses thereof
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN101453993A (zh) 2006-04-03 2009-06-10 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2016076A2 (fr) * 2007-01-22 2009-01-21 Teva Pharmaceutical Industries Ltd. Formes polymorphes d'hydrobromure de rosiglitazone et leurs procédés de préparation
WO2008121496A1 (fr) * 2007-03-30 2008-10-09 Tioga Pharmaceuticals Inc. Agonistes du récepteur opiacé kappa pour le traitement du syndrome du côlon irritable avec alternance ou à diarrhée prédominante
US20090318520A1 (en) 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
EP2635296B1 (fr) * 2010-11-03 2014-12-24 Arecor Limited Nouvelle composition contenant de glucagon
DK2916852T3 (en) * 2012-11-06 2021-05-10 Sigrid Therapeutics Ab A porous silica material for use as a pharmaceutical or dietary active ingredient
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (fr) 2017-03-01 2018-09-07 Rgenix, Inc. Sels pharmaceutiquement acceptables d'acide bêta-guanidinopropionique ayant des propriétés améliorées et utilisations de ceux-ci
AU2020402994A1 (en) 2019-12-11 2022-06-23 Inspirna, Inc. Methods of treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030174C (fr) * 1990-01-10 1996-12-24 Anthony H. Cincotta Procede pour la reduction a long terme des reserves lipidiques, de l'insulinoresistance, de l'hyperinsulinemie et de l'hypoglycemie chez les vertebres
GB9111426D0 (en) 1991-05-28 1991-07-17 Ici Plc Chemical compounds
DE69219136T2 (de) * 1991-08-26 1997-08-28 Pharmacia & Upjohn Co., Kalamazoo, Mich. Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CA2244831A1 (fr) * 1996-02-02 1997-08-07 John T. Olson Methode de traitement du diabete et d'etats pathologiques associes
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
US6329403B1 (en) 2001-12-11
KR20010043455A (ko) 2001-05-25
ES2255316T3 (es) 2006-06-16
WO2000000195A1 (fr) 2000-01-06
DE69929996T2 (de) 2006-11-16
EP1093370B1 (fr) 2006-02-22
CA2329004A1 (fr) 2000-01-06
US20020086885A1 (en) 2002-07-04
DE69929996D1 (de) 2006-04-27
CA2329004C (fr) 2009-04-14
AR019727A1 (es) 2002-03-13
NO20006630D0 (no) 2000-12-22
EP1093370A1 (fr) 2001-04-25
DK1093370T3 (da) 2006-05-22
AU4291499A (en) 2000-01-17
CN1305376A (zh) 2001-07-25
AU754740B2 (en) 2002-11-21
NO20006630L (no) 2001-02-26
ATE318138T1 (de) 2006-03-15
ZA200006262B (en) 2001-11-02
BR9911656A (pt) 2001-03-20

Similar Documents

Publication Publication Date Title
ID27415A (id) Komposisi farmaseutik
NO20005913D0 (no) Legemiddelsammensetning
EA199900373A3 (ru) Фармацевтические композиции
NO20015175D0 (no) Farmasöytisk sammensetning
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
ID29262A (id) Komposisi farmasi
FI991485A0 (fi) Uusi farmaseuttinen koostumus
ID29089A (id) Sediaan farmasi moksifloksasin
DK1466615T3 (da) Farmaceutisk præparat
DE69942892D1 (de) Gaserzeugende zusammensetzung
DE69928862D1 (de) Zusammensetzung
ID27201A (id) Komposisi farmasi
ID27150A (id) Sediaan levotiroksin bahan farmasi
ID29294A (id) Komposisi farmasi
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
ID30032A (id) Formulasi farmasi
ID25857A (id) Komposisi farmasi
FI4488U1 (fi) Farmaseuttinen koostumus
ID18698A (id) Komposisi farmasi
EE200100281A (et) Analgeetiline ravimkoostis
ID26215A (id) Komposisi farmasi
ITMI962628A0 (it) Composizione farmaceutica
DE69939964D1 (de) Gelförmige Zusammensetzung
ID23531A (id) Komposisi farmasi
FI981567A0 (fi) Farmaseuttiset koostumukset